Modular, scalable, and fast, the company’s next-generation, bi-directional CRISPR-based synthetic lethality discovery engine, EVOLVETM, can precisely and directly identify the paired genetic interactions that form the basis for breakthrough targets and first-in-class cancer drugs. Cutting-edge functional genomics and computational analysis accelerate the discovery of de-risked, druggable targets with the ultimate goal of improving patient outcomes, minimizing toxicity, and quickening development in defined patient subsets.
Tavros is leveraging its proprietary platform and synthetic lethal map to build a highly innovative pipeline of category-defining small-molecule drug candidates. In addition to developing drugs internally, Tavros has also built a strong foundation of partnerships and collaborations to expand our impact to patients.
